Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something

Z L Rana Kaplan^{1

2}, Nikki van Leeuwen¹, Eduardus F M Posthuma^{3

4}, Otto Visser⁵, Gerwin Huls⁶, Arjan A van de Loosdrecht⁷, Avinash G Dinmohamed^{8

9

10}

Affiliations

¹ Center for Medical Decision Making, Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
³ Department of Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.
⁴ Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
⁵ Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁶ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
⁷ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
⁸ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. a.dinmohamed@iknl.nl.
⁹ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.dinmohamed@iknl.nl.
¹⁰ Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. a.dinmohamed@iknl.nl.

Z L Rana Kaplan et al. Leukemia. 2022 Feb.

. 2022 Feb;36(2):596-598.

doi: 10.1038/s41375-021-01503-y. Epub 2022 Jan 17.

Z L Rana Kaplan^{1

2}, Nikki van Leeuwen¹, Eduardus F M Posthuma^{3

4}, Otto Visser⁵, Gerwin Huls⁶, Arjan A van de Loosdrecht⁷, Avinash G Dinmohamed^{8

9

10}

¹ Center for Medical Decision Making, Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
³ Department of Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.
⁴ Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
⁵ Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁶ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
⁷ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
⁸ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. a.dinmohamed@iknl.nl.
⁹ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.dinmohamed@iknl.nl.
¹⁰ Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. a.dinmohamed@iknl.nl.

No abstract available

References

1. Martinez-Cuadron D, Serrano J, Gil C, Tormo M, Martinez-Sanchez P, Perez-Simon JA, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. 2021;35:1571–85. https://doi.org/10.1038/s41375-020-01058-4 . Epub 2020 Oct 19.
1. Estey E. New treatments for acute myeloid leukemia: how much has changed? Leukemia. 2021;35:45–6. - DOI
1. Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012. Leukemia. 2016;30:24–31. - DOI
1. Henson DE, Ries LA. The relative survival rate. Cancer. 1995;76:1687–8. - DOI
1. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51–64. - DOI